Nuclear Medicine Radioisotopes Market to Reach US$ 13.98 Billion by 2033 at 8.9% CAGR; North America Leads with 40% Share - Key Players: NTP Radioisotopes, Nordion, Cardinal Health

Nuclear Medicine Radioisotopes Market reached US$ 6.51 billion in 2024 and is expected to reach US$ 13.98 billion by 2033, growing at a CAGR of 8.9% during the forecast period 2025-2033. The market is expanding steadily due to the rising adoption of nuclear imaging and targeted radionuclide therapies in oncology, cardiology, and neurology. Increasing prevalence of cancer and cardiovascular diseases, along with the growing use of PET and SPECT imaging techniques, is significantly driving demand for diagnostic and therapeutic radioisotopes worldwide.

Market growth is further supported by advancements in radiopharmaceutical development, increased investments in cyclotron and reactor infrastructure, and the emergence of theranostics combining diagnosis and therapy using the same radioisotope. Isotopes such as Technetium-99m, Fluorine-18, Iodine-131, and Lutetium-177 are widely used for disease detection and treatment, particularly in precision oncology. Additionally, expanding healthcare infrastructure in emerging economies, favorable regulatory approvals, and ongoing collaborations between hospitals, research institutes, and radioisotope producers are strengthening the global nuclear medicine radioisotopes market outlook.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/nuclear-medicine-radioisotopes-market?sai-v

The Nuclear Medicine Radioisotopes Market is the sector that produces and supplies radioactive isotopes used in diagnostic imaging and targeted therapies within nuclear medicine.

Key Developments
✅ October 2025: Medical imaging and therapeutic centers in North America administered radioisotopes such as technetium-99m and fluorine-18 for diagnostic imaging (e.g., PET, SPECT) and therapeutic procedures.

✅ September 2025: European hospitals and nuclear medicine departments utilized radioisotopes produced by cyclotrons and nuclear reactors for oncology diagnostics and treatment planning.

✅ August 2025: Asia-Pacific nuclear medicine facilities implemented quality control and supply chain management practices for medical radioisotope delivery to imaging and therapeutic units.

✅ July 2025: Technology providers supplied standardized radiopharmaceutical kits containing radioisotopes for use in diagnostic assays and nuclear imaging procedures.

✅ May 2025: Nuclear medicine departments in hospitals and clinics processed radioisotope doses under licensed handling, shielding, and safety protocols for patient procedures.

✅ March 2025: Regulatory authorities reviewed and enforced licensing, transport, and radiation safety standards applicable to medical radioisotope use in nuclear medicine.

Mergers & Acquisitions
✅ November 2025: A healthcare technology or radiopharmaceutical company acquired a radioisotope production facility to integrate supply of medical isotopes with imaging and therapy services.

✅ August 2025: A European nuclear medicine solutions provider partnered with a cyclotron manufacturer to secure radioisotope supply for regional diagnostic and therapeutic use.

✅ June 2025: An Asia-Pacific medical technology company acquired operations of a radioisotope distribution firm to extend delivery services to imaging centers and hospitals.

Key Players
NTP Radioisotopes SOC Ltd | Nordion Inc. (Sotera Health Company) | Cardinal Health, Inc. | Bayer AG | GE Healthcare | NorthStar Medical Radioisotopes, LLC | Others

Key Highlights
NTP Radioisotopes SOC Ltd holds a share of 26.8 percent, supported by its dominant position in global medical radioisotope production, particularly molybdenum-99, and long-standing supply relationships with nuclear medicine providers worldwide.

Nordion Inc. (Sotera Health Company) accounts for 21.4 percent, leveraging its expertise in radioisotope processing, distribution infrastructure, and strong presence in diagnostic nuclear medicine applications.

Cardinal Health, Inc. represents 17.9 percent, driven by its extensive healthcare distribution network, integrated radiopharmaceutical services, and strong hospital partnerships.

GE Healthcare captures 14.6 percent, supported by its vertically integrated nuclear imaging portfolio, radioisotope production capabilities, and global footprint in diagnostic imaging systems.

Bayer AG holds 11.2 percent, benefiting from its established radiopharmaceutical products, oncology-focused nuclear medicine therapies, and strong regulatory and commercialization capabilities.

NorthStar Medical Radioisotopes, LLC accounts for 6.1 percent, gaining traction through non-reactor-based isotope production technologies and growing adoption in domestic and international healthcare markets.

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=nuclear-medicine-radioisotopes-market?sai-v
(Purchase 2 or more Reports and get 50% Discount)

Market Drivers
- Rising prevalence of cancer, cardiovascular diseases, and neurological disorders driving demand for nuclear medicine diagnostics and therapies.

- Growing adoption of radioisotopes in PET and SPECT imaging for accurate disease detection, staging, and treatment monitoring.

- Expansion of theranostics-paired diagnostic and therapeutic radioisotope applications, for personalized patient care.

- Advancements in radioisotope production technologies, including cyclotrons and generator systems.

- Supportive government and healthcare initiatives promoting early disease diagnosis and precision medicine.

- Rising investments in nuclear medicine infrastructure and radiopharmacy facilities.

- Increasing clinical evidence and acceptance of radioisotope-based procedures improving patient outcomes.

Industry Developments
- Expansion of production capacity for key diagnostic and therapeutic radioisotopes such as Technetium-99m, Iodine-131, and Fluorine-18.

- Launch of new PET and SPECT tracers targeting oncology, cardiology, and neurology applications.

- Growing collaborations between hospitals, radiopharmacies, research institutions, and isotope manufacturers.

- Development of advanced radiochemistry technologies enabling higher purity and yield.

- Increased adoption of automated synthesis and dispensing systems enhancing safety and workflow efficiency.

- Rising mergers, acquisitions, and strategic investments in radioisotope supply chain and nuclear medicine services.

- Expansion of clinical trials evaluating novel radioisotopes for diagnosis and therapy.

Regional Insights
North America - 40% share: "Driven by advanced nuclear medicine infrastructure, high prevalence of chronic diseases, strong R&D investment, and supportive reimbursement policies."

Europe - 30% share: "Supported by well-established nuclear medicine networks, growing theranostics adoption, and strong regulatory frameworks."

Asia Pacific - 24% share: "Fueled by rising healthcare expenditure, expanding diagnostic imaging demand, increasing cancer burden, and investments in isotope production."

Latin America - 4% share: "Boosted by improving access to advanced imaging services, growing radiopharmacy initiatives, and rising diagnostic awareness."

Middle East & Africa - 2% share: "Driven by healthcare modernization efforts, expansion of nuclear medicine centers, and rising adoption of diagnostic and therapeutic radioisotopes."

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/nuclear-medicine-radioisotopes-market?sai-v

Key Segments
By Type of Radioisotopes
Technetium-99m (Tc-99m) dominates the market due to its widespread use in diagnostic imaging, favorable half-life, and cost-effectiveness, making it a standard radioisotope in nuclear medicine procedures. Fluorine-18 holds a significant share, driven by its extensive application in PET imaging, particularly for oncology and neurological diagnostics. Iodine-123 is widely adopted for thyroid imaging owing to its optimal imaging characteristics and lower radiation dose. Thallium-201 continues to be used in cardiac imaging, especially for myocardial perfusion studies, despite gradual substitution by newer agents. Rubidium-82 is gaining traction in PET-based cardiac imaging due to its short half-life and ability to provide high-quality perfusion images. Therapeutic radioisotopes such as Iodine-131, Lutetium-177, Radium-223 (Alpharadin), and Actinium-225 are witnessing strong growth, supported by increasing adoption of targeted radionuclide therapies in oncology. Other radioisotopes continue to serve specialized diagnostic and therapeutic applications across nuclear medicine.

By Application
Oncology represents the largest application segment, driven by the growing use of radioisotopes in cancer diagnosis, staging, and targeted radiotherapy. Cardiology holds a significant share as nuclear imaging plays a critical role in assessing myocardial perfusion, cardiac function, and coronary artery disease. Thyroid applications remain a core segment due to the long-standing use of radioisotopes for both diagnosis and treatment of thyroid disorders. Neurology is experiencing steady growth, supported by increasing use of PET and SPECT imaging in the evaluation of neurological disorders such as Alzheimer's disease and epilepsy. Other applications, including nephrology, pulmonology, and infection imaging, contribute to the overall expansion of the market.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.